Angiogenesis of gastrointestinal tumours and their metastases - A target for intervention?

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1302-1313

  Garcea, G ^a   Lloyd, T D ^b   Gescher, A ^a   Dennison, A R ^b   Steward, W P ^a   Berry, D P ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis and anti angiogenesis therapy; Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [2 (4 DIMETHYLPYRROL 5 YL)METHYLIDENYL]INDOLIN 2 ONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; ANTISENSE OLIGONUCLEOTIDE; DNA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMCITABINE; HEME OXYGENASE; HYPOXIA INDUCIBLE FACTOR 1; INTEGRIN; INTEGRIN ANTAGONIST; INTERLEUKIN 8; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RIBOZYME; SCLEROPROTEIN; SU 5146; THROMBOSPONDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INVASION; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; EXTRACELLULAR MATRIX; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TUMOR; HUMAN; HYPOXIA; LIVER METASTASIS; METASTASIS; METASTASIS INHIBITION; MOLECULAR BIOLOGY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 2942557161     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.015     Document Type: Article

References (152)

1. Reinmuth N., Parkh A., Ahamad S., Liu W., Stoeltzing O., Fan F., et al. Biology of angiogenesis in tumours of the gastrointestinal tract. Microsc. Res. Tech. 60:2003;199-207
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31
3. Folkman J. What is the evidence that tumours are angiogenesis dependent? Natl. Cancer Inst. 82:1990;4-6
4. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? GHA. Clowes memorial Award Lecture. Cancer Res. 46:1986;467-473
5. Liotta L.A., Kohn E.C. The microenvironment of the host-tumour interface. Nature. 411:2001;375-379
6. Carmeliat P., Jain R.K. Angiogenesis in cancer and other diseases. Nat. Med. 407:2000;249-257
7. Tischer E., Mitchell R., Hartman T., Silva M.D.G., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple proteins are encoded thorugh alternative axon splicing. J. Biol. Chem. 266:1991;11947-11954
8. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol. Cancer. 2:2003;1-8
9. Nor J.E., Christensen J., Mooney D.J., Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:1999;375-384
10. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309
11. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 265:1993;H586-H592
12. Pepper M.S., Ferrara N., Orci L.R.M. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181:1991;902-906
13. Ellis L.M., Yutaka T., Wenviao L., Shaheen R.M. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 5:2000;11-15
14. Ferrer F.A., Miller L.J., Lindquist R. Expression of vascular endothelial growth factor receptors in prostate cancer. Urology. 54:1999;567-572
15. Shiraishi A., Ishiwata T., Shoji T., Asano G. Expression of PCNA, basic fibroblast growth factor, FGF receptor and vascular endothelial growth factor in adenomas and carcinomas of human colon. Acta Histochem. Cytochem. 28:1995;21-29
16. Takahashi Y., Tucker S.L., Kitadai Y., Koura A.N., Bucana C.D., Cleary K.R., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 132:1997;541-546
17. Wong M.P., Cheung N., Yuen S.T., Leung S.Y., Chung S.P. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int. J. Cancer. 81:1999;845-850
18. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L. Expression of vascular endothelial growth factor and its receptor KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res. 55:1995;3964-3968
19. Kang S.M., Maeda K., Onoda N., Chung Y.S., Nakata B., Nishiguchi Y., et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumour vascularity and liver metastasis. Int. J. Cancer. 74:1997;502-507
20. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer. 78:1998;1379-1384
21. Takahashi Y., Bucana C.D., Akagi Y., Liu W., Cleary K.R., Mai M., et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin. Cancer Res. 4:1998;429-434
22. Konno S., Takebayashi Y., Aiba M., Akiyama S., Ogawa K. Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett. 166:2001;103-111
23. Kimura H., Konishi K., Nukui T., Kaji M., Maeda K., Yabushita K., et al. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric cancer. J. Surg. Oncol. 76:2001;31-36
24. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 77:1996;858-863
25. Karayiannakis A.J., Bolanaki H., Syrigios K.N., Asimakopoulos B., Polychronidis A., Anagnostoulis S., et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett. 194:2003;119-124
26. Liu C.D., Tilch L., Kwan D., McFadden D.W. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J. Surg. Res. 102:2002;31-34
27. Niedergethmann M., Hildenbrand R., Westbrook B., Hartel M., Sturm J.W., Richter A., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas. 25:2002;122-129
28. Ellis L.M., Takahsi Y., Fenoglio C.J., Cleary K.R., Bucana D.D., Evans D.B. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer. 34:1998;337-340
29. Ikeda N., Adachi M., Taki T., Huang C., Hashida H., Takabayashi S., et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer. 79:1999;1553-1563
30. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet derived growth factor. Physiol. Rev. 79:1999;1283-1316
31. Cao R., Brackenhielm E., Li X., Pietras K., Widenfalk J., Ostman A., et al. Angiogenesis stimulated by PDGF-CC, a novel member of the PDGF family, involves activation of PDGFR-alphaalpha and alphabeta receptors. FASEB. 16:2002;1575-1583
32. Li X., Eriksson U. Novel PDGF family members: PDGFC and PDGF-D. Cytokine Growth Factor Rev. 14:2003;91-98
33. Bergsten E., Uutela M., Pietras K., Ostman A., Heldin C.H., Alitalo K., et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell Biol. 3:2001;512-516
34. LaRochelle W.H., Jeffers M., McDonald W.F., Chillakuru R.A., Giese N.A., Lokker N.A., et al. PDGF-D, a new protease-activated growth factor. Nat. Cell Biol. 3:2001;517-521
35. Ostman A., Heldin C.H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80:2001;1-38
36. Li H., Fredickson L., Li X., Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 22:2003;1501-1510
37. Crosby J.R., Tappan K.R., Seifert R.A., Bowen-Pope D.F. Chimera analysis reveals that fibroblasts and endothelial cells require platelet-derived growth fatorbeta expression for participation in reactive connective tissue formation in adults but not during development. Am. J. Pathol. 154:1999;1315-1321
38. Sachinidis A., Locher R., Hoppe J., Vetter W. The platelet-derived growth factor isomers, PDGF-AA, PDGF-AB and PDGF-BB induce contraction of vascular smooth muscle cells by different intracellular mechanisms. FEBS. 275:1990;95-98
39. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 338:1989;557-562
40. Moghaddam A., Zahang H.T., Fan T.P., Hu D., Lees V.C., Turley H., et al. Thymidine phosphorylase is angiogenic and promotes tumour growth. Nature. 92:1995;998-1002
41. Takahashi Y., Bucana C.D., Liu W., Yoneda J., Kitadai Y., Cleary K.R., et al. Platelet-derived endothelial growth factor in human colon cancer angiogenesis: role of infiltrating cells. J. Natl. Cancer Inst. 88:1996;1146-1151
42. Kikuyama S., Inada T., Shimizu K., Miyakita M. Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis. Anticancer Res. 20:2000;2081-2086
43. Fujimoto K., Hosotani R., Wada M., Lee J.U., Koshiba T., Miyamato Y., et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet derived endothelial cell growth factor in human pancreatic cancer. Eur. J. Cancer. 34:1998;1439-1447
44. Peters K.G. Vascular endothelial growth factor and the angiopoietins; working together to build a better blood vessel. Circ. Res. 83:1998;342-343
45. Tsigkos S., Koutsilieris M., Papepetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin. Exp. Drugs. 6:2003;933-941
46. Ellis L., Ahamad S., Fan F., Liu W., Jung Y.D., Stoeltzing O., et al. Angiopoietins and their role in colon cancer angiogenesis. Oncology. 16:2002;31-35
47. Masonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoieitn-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60
48. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel co-option, regression and growth in tumours mediated by angiopoietins and VEGF. Science. 284:1999;1994-1998
49. Ahamad S., Liu W., Jung Y.D., Fan F., Reimuth N., Bucana C.D., et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. Cancer. 92:2001;1138-1143
50. Ahamad S., Liu W., Jung Y.D., Fan F., Wilson M., Reimuth N., et al. The effects of angiopoietin-1 and angiopoietin-2 on tumour growth and angiogenesis in human colon cancer. Cancer Res. 61:2001;1125-1259
51. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., Mori M. Angiopoietin-2 is related to tumour angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 61:2001;2145-2153
52. Shimoyama S., Gansauge F., Gansuage G., Negri G., Oohara T., Teger B.H. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res. 56:1996;2703-2706
53. August P., Javerzat S., Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res. 8:2003;204-210
54. Montesano R., Vassalli J.D., Baird A., Guillemin R., Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Acad. Sci. USA. 83:1986;7297-7301
55. Johnson D.E., Lu J., Chen H., Werner S., Williams L.T. The human fibroblast growth receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol. Cell. Biol. 11:1991;4627-4634
56. Nakamura T., Mochizuki Y., Kanetake H., Kanda S. Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem. Biophys. Res. 289:2001;801-806
57. Javerzat S., August P., Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol. Med. 8:2002;483-489
58. Arbeit J.M., Olson D.C., Hanahan D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene. 13:1996;1847-1857
59. Kwan D., Venkataraman G., Shriver Z., Raman R., Liu D., Qi Y., et al. Probing fibroblast growth factor dimidiation and role of heparin-like glycosaminoglycans in modulating dimerization and signalling. J. Biol. Chem. 276:2001;23421-23429
60. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual for heparin in FGFR binding and dimeration. Mol. Cell. 6:2000;743-750
61. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer. J. Natl. Cancer Inst. 86:1994;356-361
62. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor, in the urine of bladder cancer patients. J. Natl. Cancer Inst. 85:1993;241-242
63. Landriscina M., Cassano A., Ratto C., Longo R., Ippoliti M., Palazotti F., et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br. J. Cancer. 78:1998;765-770
64. Galzie Z., Fernig D.G., Smith J.A., Poston G.J., Kinsella A.R. Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factor. Int. J. Cancer. 71:1997;390-395
65. George M.L., Tutton M.G., Abulafi A.M., Eccles S.A., Swift R.I. Plasma basic fibroblast growth factor levels in colorectal cancer, a clinically useful assay? Clin. Exp. Met. 19:2002;735-738
66. Grotowski M., Piechota W. Receptors of selected cytokines and angiokine bFGF in patients with colorectal cancer. Pol. Merkuriusz Lek. 11:2001;398-401
67. Dirix L.Y., Vermeulen P.B., Pawinski A., Prove A., Benoy I., De Pooter C., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer. 76:1997;238-243
68. Dirix L.Y., Vermeulen P.B., Hubens G., Benoy I., Martin M., De Pooter C., et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann. Oncol. 7:1996;843-848
69. Tanimoto H., Yoshida K., Yokozaki H., Yasui W., Nakayama H., Ito H., et al. Expression of basic fibroblast growth factor in human gastric cancers. Virchows Arch. B: Cell Pathol. Incl. Mol. Pathol. 61:1991;263-267
70. Noda M., Hatori T., Kimura H., Naitoh H., Kodama T., Kashima K., et al. Expression of fibroblast growth factor 2 mRNA in early and advanced gastric cancer. Acta Oncol. 36:1997;695-700
71. Ueki T., Koji T., Tamiya S., Nakane P.K., Tsuneyoshi M. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J. Pathol. 177:1995;353-361
72. Yoshikawa T., Tsuburaya A., Kobayashi O., Sairenji M., Motohashi H., Yanoma S., et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett. 29:2000;7-12
73. Anazai H., Kitadai Y., Bucana C.D., Sanchez R., Omoto R., Fidler I.J. Expression of metastasis-related genes in surgical specimens human gastric cancer can predict disease recurrence. Eur. J. Cancer. 34:1998;558-565
74. Estival A., Durand S., Clerc P., Louvel D., Vaysse N., Valdiguie P., et al. Pancreatic cancer cell regulation by lipids and by basic fibroblast growth factor expression. Cancer Detect. Prev. 21:1997;546-552
75. Ghaneh P., Kawesha A., Evans J.D., Neoptolemos J.P. Molecular prognostic markers in pancreatic cancer. J. Hepatobiliary Pancreat. Surg. 9:2002;1-11
76. Fujioka S., Yoshida K., Yanagisawa S., Kawakami M., Aoki T., Yamaza Y. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoural microvessel density as independent predictors of overall and relapse-free survival. Cancer. 92:2001;1788-1797
77. Ohta T., Yamamoto M., Numata M., Iseki S., Tsukioka Y., Miyashita T., et al. Expression of fibroblast growth factor and its receptor in human pancreatic carcinomas. Br. J. Cancer. 72:1995;824-831
78. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-inducible factor-1 is basic-helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension. Proc. Natl. Acad. Sci. USA. 92:1995;5510-5514
79. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., et al. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res. 60:2000;7075-7083
80. Wenger R.H., Gassmann M. Oxygen and the hypoxia-inducible factor 1. Biol. Chem. 378:1997;609-616
81. Bunn H.F., Polyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 76:1996;839-885
82. Semenza G.L. Regulation of mammalian oxygen homeostasis by hypoxia inducible factor 1. Annu. Rev. Cell Dev. Biol. 15:1999;551-578
83. Cangul H., Salinokow K., Yee H., Zagzag D., Commes T., Costa M. Enhanced expression of an HIF-1/hypoxia-related protein in cancer cells. Environ. Health Perspect. 110:2002;738-788
84. Kuwai T., Kitadai Y., Tanaka S., Onogowa A., Matsutani N., Kaio E., et al. Expression of hypoxia inducible factor-1 alpha is associated with tumour vascularisation in human colorectal carcinomas. Int. J. Cancer. 105:2003;176-181
85. Zhong H., De Marzo A.M., Laugner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835
86. Krishnamachanary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferro G., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63:2003;1138-1143
87. Jiang Y.A., Fan F., Jiang C.Q., Zhang Y.Y., Luo H.S., Tang Z.J., et al. Expression and significance of PTEN, hypoxia inducible factor alpha in colorectal adenoma and adenocarcinoma. World J. Gastroenterol. 9:2003;491-494
88. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatiylinositol 3-kinase signalling in colon cancer cells. J. Biol. Chem. 277:2002;38205-38211
89. Buchler P., Reber H.A., Buchler M., Shrinkante S., Buchler M.W., Firess H., et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 26:2003;56-64
90. Akakura N., Kobayashi O., Horiuchi I., Suzuki A., Wang G.L., Chen J., et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61:2001;6548-6554
91. Brew R., Eriksson U., West D.C., Kinsella A.R., Slavin J., Christmas S.E. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine. 12:2000;78-85
92. Brew R., Erikson J.S., West D.C., Flanagan B.F., Christmas S.E. Interleukin-8 as a growth factor for human colorectal carcinoma cells in vitro. Biochem. Soc. Trans. 25:1997;246S
93. Takeda A., Stoeltzing O., Ahamad S., Reimuth N., Liu W., Fan F., et al. Role of angiogenesis in the development and growth of liver metastasis. Ann. Surg. Oncol. 9:2002;610-616
94. Haraguchi M., Komuta K., Akashi A., Matsuzaki S., Furui J., Kanematsu T. Elevated IL-8 levels in the drainage vein of resectable Dukes C colorectal cancer indicate high risk for developing hepatic metastasis. Oncol. Rep. 9:2002;159-165
95. Kitadai Y., Takahashi Y., Haruma K., Naka K., Sumii K., Yokozaki H., et al. Transfection of interlukin-8 increases angiogenesis and tumourigenesis of human gastric carcinoma cells in nude mice. Br. J. Cancer. 81:1998;647-653
96. Kitadai Y., Haruma K., Sumii K., Yamamoto S., Ue T., Yokozaki H., et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am. J. Pathol. 152:1998;93-100
97. Kido S., Kitadai Y., Hattori N., Haruma K., Kido T., Ohta T., et al. Interluekin 8 and vascular endothelial growth facor; prognostic facotrs in human gastric carcinomas. Eur. J. Cancer. 37:2001;1482-1487
98. Kuwada Y., Sasaki T., Morinaka K., Kitadai Y., Mukaida N., Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int. J. Oncol. 22:2003;765-771
99. Ivaska J., Heino J. Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell. Mol. Life Sci. 57:2000;16-24
100. Hynes R.O. Integrins: versatility, modulation, and signalling in cell adhesion. Cell. 69:1992;11-25
101. Ruegg C., Marriot A. Vascular integrins: pleiotropic adhesion and signalling molecules and vascular homeostasis and angiogenesis. Cell. Mol. Life Sci. 60:2003;1135-1157
102. Urah H., Denno R., Hirata K., Yamaguchi K., Yasahimo T. Separate functions of alpha2beta1 and alhpah2beta1 integrins in the metastatic process of human gastric carcinoma. Surg. Today. 28:1998;1001-1006
103. Reinmuth N., Liu W., Ahamad S. The (v)-(3) inhibitor S247 decreases colon cancer metastasis, angiogenesis and improves survival in a murine model of liver metastasis. Clin. Cancer Res. 7:2001;A24
104. Baenzinger N.L., Brodie G.N., Majerus P.W. Isolation and properties of a thrombin-sensitive protein of human platelets. J. Biol. Chem. 247:1972;2723-2731
105. Miyanaga K., Kato Y., Nakamura T., Amaya H., Horiuchi I., Chiba Y., et al. Expression and role of thromobspondin-1 in colorectal cancer. Anticancer Res. 22:2002
106. Maeda K., Nishiguchi Y., Yashiro M., Yamada M., Onoda N., Sawada T., et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int. J. Mol. Med. 5:2000;373-378
107. Tomii Y., Kamochi J., Yamazaki H., Sawada T., Tokunaga T., Ohnishi Y., et al. Human thrombospondin-2 inhibits proliferation of microvascular endothelial cells. Int. J. Oncol. 20:2002;339-342
108. Tokunaga T., Nakamura M., Oshika Y., Abe Y., Ozeki Y., Fukushima Y., et al. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colorectal cancer. Br. J. Cancer. 79:1999;354-359
109. Kasper H.U., Ebert M., Malfertheiner P., Roessner A., Kirkpatrick C.J., Wolf H.K. Expression of thrombospondin-1 in pancreatic cancer: correlation with microvessel density. Virchows Arch. 438:2001;116-120
110. Zhang J., Ito R., Oue N., Zhu X., Kitadai Y., Yoshida K., et al. Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch. 442:2003;563-568
111. Tobita K., Kijima H., Dowaki S., Oida Y., Kashiwagi H., Ishii M., et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int. J. Oncol. 21:2002;1189-1195
112. Tenhunen R., Marver H.S., Schmid R. The enzymatic catabolism of haem to bilirubin by microsomal haem oxygenase. Proc. Natl. Acad. Sci. USA. 61:1970;748-755
113. Motterlini R., Forest R., Bassi R., Calabrese V., Clark J.E., Green C.J. Endothelial haem oxygenase-1 induction by hpoxia. Modulation by inducible nitric-oxide synthase and S-nitrosthiols. J. Biol. Chem. 275:2000;13613-13620
114. Kim Y.M., Bergonia H., Lancaster J.R. Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. FEBS. 374:1995;228-232
115. Keyse S.M., Tyrrell R.M. Haem oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide and sodium peroxide. Proc. Natl. Acad. Sci. USA. 86:1989;99-103
116. Tanaka S., Akaike T., Fang J., Beppu T., Ogawa M., Tamura F., et al. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br. J. Cancer. 24:2003;902-909
117. Doi K., Akaike T., Fujii S., Tanaka S., Ikebe N., Beppu T., et al. Induction of haem oxygenase-1 nitric oxide and ischemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer. 80:1999;19945-19954
118. Sly W.S., Hu P.Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu. Rev. Biochem. 64:1995;375-401
119. Saarnio J., Parkkila S., Parkkila A.K., Haukipuro K., Patorkova M., Pastorek J., et al. Immunohistochemical study of colorectal tumours for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 153:1998;279-285
120. Kivela A.J., Parkkila A.K., Saarnio J., Karttunen T.J., Kivela A., Parkkila S., et al. Expression of a novel transmembrane carbonic anydrase enzyme XII in normal human gut and colorectal tumours. Am. J. Pathol. 156:2000;577-584
121. Kivela A.J., Saarnio J., Karttunen T.J., Kivela J., Parkkila A.K., Pastoerkova S., et al. Differential expression of cytoplasmic carbonic anhydrases, CA I and CA II and membrane-associated isoenzymes, CA IX and CA XII in normal mucosa of large intestine and in colorectal tumours. Dig. Dis. Sci. 46:2001;2179-2186
122. Bekku S., Mochizuki Y., Yammato T., Ueno H., Takayama E., Tadakuma T. Expression of carbonic anydrase II or II and correlation to clinical aspects of colorectal cancer. Hepatogastroenterology. 47:2000;998-1001
123. Yokoyama S., Shatney C.H., Mochizuki H., Hase K., Johnson D.L., Cummings S., et al. The potential role of carbonic anhydrase II in screening for colorecta cancer. Am. Surg. 63:1997;243-246
124. Paku S., Lapis K. Morphological aspects of angiogenesis in experimental liver metastases. Am. J. Pathol. 143:1993;926-936
125. Richard D.E., Berra E., Poyssegur J. Angiogenesis: how a tumour adapts to hypoxia. Biochem. Biophys. Res. 266:1999;718-722
126. Bernery C.R., Yang J.L., Fisher R.J., Russel P.J., Crowe P.J. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res. 18:1998;973-977
127. Cascinu S., Graziano F., Catalano V., Staccioli M.P., Barni S., Giordani P., et al. Differences in vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases. Clin. Exp. Met. 18:2001;651-655
128. Vermeulen P.B., Colpaert C., Salgado R., Royers R., Hellemans H., Van den Heuvel E., et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 195:2001;336-342
129. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micro metastases; balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:1995;149-153
130. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of target both pericytes and endothelial cells in the tumour vasculature with kinase inhibitors. J. Clin. Invest. 111:2003;1287-1295
131. Shaheen R.M., Davis D.W., Liu W., Zebrowski B.K., Wilson M.R., Bucana C.D., et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colorectal cancer liver metastasis and induces tumour and endothelial cell apoptosis. Cancer Res. 59:1999;5412-5416
132. De Primo SE, Wong LM, B. KD, Nicholas SL, Manning WC, Smolich BD, et al. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical cancer trial: a novel strategy for biomarker indentification. BMC Cancer 2003, 7; 7:3
133. Laird A.D., Vajkoczy P., Shawver L.K., Thurnher A., Liang C., Mohammadi M., et al. SU6668 is a potent antiangiogenic and antitumour agent that induces regression of established tumours. Cancer Res. 60:2000;4152-4160
134. Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., et al. Tyrosine kinase inhibition of mulptile angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastses by inhibition of endothelial cell survival mechanisms. Cancer Res. 61:2001;1464-1468
135. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., et al. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60:2000;2935-2962
136. Baker C.H., Solorzano C.C., Fidler I.J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signalling for therapy of metastatic human pancreatic cancer. Cancer Res. 62:2002;1996-2003
137. Thomas A.L., Morgan B., Drevs J., Unger C., Widenemann B., Vanhoefer U., et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584. Semin. Oncol. 30:2003;32-38
138. Shaheen R.M., Tseng W.W., Vellagas R., Liu W., Ahmad S., Jung Y.D., et al. Effects of an antibody to vascular endothelial growth factor receptor-2 survival on survival, tumour vascularity and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 2:2003;221-226
139. Shaheen R.M., Ahamad S., Liu W., Reinmuth N., Jung Y.D., Tseng W.W., et al. Inhibited growth of colon carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer. 17:2001;584-589
140. Park K.R., Ferrara N., Jain R.K., Suit H.D., Boucher Y. Anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions. Cancer Res. 60:2000;5565-5570
141. Bruns C.J., Shrader M., Harbison M.T., Portera C., Solorzano C.C., Jauch K.W., et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthoptically in nude mice. Int. J. Cancer. 102:2002;101-108
142. Jung Y.D., Mansfield P.F., Akagi M., Takeda A., Liu W., Bucana C.D., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur. J. Cancer. 20:2002;1133-1140
143. Okamato K., Oshika Y., Fukushima Y., Yoshimura M., Oshishi Y., Tokunaga T., et al. Inhibition of liver metastasis of colon cancer by in vivo administration of anti-vascular endothelial growth factor antibody. Oncol. Rep. 6:1999;553-556
144. Tao H., Lin Y., Yin H., Yao M. Effect of anti-vascular endotheila growth factor antibody on the pregression of human gastric cancer orthoptic xenotransplanted into nude mice. Zhonghua Wai Ke Za Zhi. 37:1999;248-250
145. Yanagi K., Onda M., Uchida E. Effect of angiostatin on liver metastases of pancreatic cancer in hamsters. Science. 91:2000;723-730
146. Drixler T.A., Inne H., Rinkes B., Ritchie E.D., van Vroonhoven J.M., Gebbink M., et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 60:2000;1761-1765
147. Wu J., Shi Y.Q., Wu K.C., Zhang D.X., Jang J.H., Fan D. Angiostatin up-regulation in gastric cancer cell SGC7901 inhibits tumourogenesis in nude mice. World J. Gastroenterol. 9:2003;59-64
148. Yamashita Y., Sendo S., Hosokawa M., Tuszynski G., Kurohiji T., Beppu T., et al. Exogenous thrombospondin stimulates the proliferation of non-thrombospondin-producing cells. Int. J. Oncol. 13:1998;355-359
149. Pavco P.A., Bouhana K.S., Gallegos A.M., Agrawal A., Blanchard K.S., Grimm S.L., et al. Antitumour and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. 6:2000;2094-2103
150. Kamiyama M., Ischikawa Y., Ishikwawa T., Chishima T., Hasegawa S., Hamaguchi Y., et al. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther. 9:2002;197-201
151. Davis D.W., McConkey D.J., Abbruzzese J., Herbst R.S. Surrogate markers in antiangiogenesis clinical trials. Br. J. Cancer. 89:2003;8-14
152. Stoeltzing O., Liu W., Reimuth N., Fan F., Parry G.C., Parikh A.A., et al. Inhibition of integrin alpha5beta1 with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer. 104:2003;496-503